Retrospective Study
Copyright ©The Author(s) 2021.
World J Hepatol. Jan 27, 2022; 14(1): 260-273
Published online Jan 27, 2022. doi: 10.4254/wjh.v14.i1.260
Table 4 The relationship between clinicopathological factors and hepatitis B surface antigen expression patterns with viral response and serological response

HBeAg positive
HBeAg negative

VR
SR
VR
ParametersAbsentPresentAbsentPresentPresent
Age (yr)
< Mean11 (34.4)39 (72.2)b19 (48.7)31 (66)b24 (44.4)
≥ Mean21 (65.6)15 (27.8)20 (51.43)16 (34)30 (55.6)
Gender
Male21 (34.4)27 (50)24 (61.5)24 (48.9)30 (55.6)
Female11 (34.4)27 (50)15 (38.5)23 (51.1)24 (44.4)
HBV DNA
Low17 (53.1)39 (72.2)a16 (41)16 (34)23 (42.6)
High15 (45.9)15 (27.8)23 (59)31 (66)31 (57.4)
HBsAg
Low21 (65.6)15 (27.8)a21 (53.8)15 (31.9)b30 (55.6)
High11 (34.4)39 (72.2)18 (46.2)32 (68.1)24 (44.4)
ALT
< 200 IU/L23 (71.9)29 (53.7)29 (74.4)23 (48.9)a39 (72.2)
≥ 200 IU/L9 (28.1)25 (46.3)10 (25.6)24 (51.1)15 (27.8)
INR
Low15 (46.9)26 (48.1)19 (48.7)22 (46.8)39 (72.2)
High17 (53.1)28 (51.9)20 (51.3)25 (53.2)15 (27.8)
Platelets
Low15 (46.9)31 (57.4)20 (51.3)26 (55.3)31 (57.4)
High17 (53.123 (42.6)19 (48.7)21 (44.7)23 (42.6)
HAI score ≥ 913 (40.6)25 (46.3)11 (25)28 (59.6)a23 (42.6)
HAI score < 919 (59.4)29 (53.7)28 (75)19 (40.4)31 (57.4)
Fibrosis ≥ 417 (53.1)16 (29.6)a17 (43.6)16 (34)20 (37)
Fibrosis < 415 (46.9)10 (70.4)22 (56.4)31 (66)34 (63)
p-HbsAg
Low26 (81.3)25 (46.3)b29 (74.4)24 (51.1)b21 (38.9)
High6 (18.8)29 (53.7)10 (25.6)23 (48.9)33 (61.1)
HBsAg SP1
A1 (3.1)16 (29.6)b2 (5.1)15 (31.9)b16 (29.6)
B010 (18.5)010 (21.3)14 (25.9)
C6 (18.8)10 (18.5)11 (28.2)5 (10.6)5 (9.3)
D6 (18.8)4 (7.4)6 (15.4)4 (8.5)6 (11.1)
E19 (59.4)14 (25.9)20 (51.3)13 (27.7)13 (24.1)
HBsAg SP2
Diffuse1 (3.1)28 (58.1)b2 (5.1)2 (57.4)b30 (55.6)
Globular12 (37.5)12 (22.2)17 (43.6)7 (14.9)10 (18.5)
Submembranous19 (59.4)14 (25.9)20 (51.3)13 (27.7)14 (25.9)
Membranous expression
Absent27 (84.4)26 (48.1)b29 (74.4)24 (51.1)b21 (38.9)
Present5 (15.6)28 (51.9)10 (25.6)23 (48.9)33 (61.1)